AstraZeneca AZN and Ionis Pharmaceuticals IONS announced that the Committee for Medicinal Products for Human Use (CHMP) has ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

Four months after the Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the ...

In a report released on November 7, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Applied Therapeutics (APLT – ...

Astellas has announced the withdrawal of its MAA for ACP from the EMA to treat geographic atrophy (GA) secondary to AMD.

Europe's Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for two vaccines: Fluad (surface antigen, inactivated, adjuvanted) and Flucelvax ...

with first data readout expected in summer 2025 European Committee for Medicinal Products for Human Use (CHMP) review of vilobelimab continues, with discussions ongoing and a CHMP opinion anticipated ...

On October 17, the EMA's Committee for Medicinal Products for Human Use concluded that the Siiltibcy skin test showed favorable results compared with two other diagnostic products. Manufactured by ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

Accord Healthcare Limited (Accord), a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company, announces that the Committee for Medicinal Products for Human Use ...